Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Jina Pharmaceuticals Inc. is managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions currently active. This level of activity indicates an ongoing effort to expand their intellectual property holdings in the pharmaceutical sector. The presence of 2 distinct art units suggests that the applications cover different technical sub-sectors within the broader biotechnology field.
The prosecution of these assets involves 2 distinct examiners, which introduces multiple perspectives into the review process. This distribution means that the company must manage different examination styles and requirements simultaneously. Having 2 distinct examiners for 2 pending office actions ensures that the workload is not concentrated under a single individual. This structure requires a coordinated approach to address the specific technical standards of each 1 distinct art unit involved.
HUANG, GIGI GEORGIANA is designated as the busiest examiner, currently overseeing 1 busiest examiner pending office action. This shows that the pending work is shared among the examiners, with each handling one of the 2 pending office actions. Practitioners should be prepared to address the specific concerns of HUANG, GIGI GEORGIANA and the other assigned examiner to move the entire portfolio forward. Monitoring the 1 busiest examiner pending office action is a key part of this strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 2 | 53.5% | +52.7% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17868358 | METHODS OF PREPARING COMPOSITIONS CONTAINING THYMOQUINONE | HUANG, GIGI GEORGIANA | 31d overdue |
| 18545418 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17868358 | METHODS OF PREPARING COMPOSITIONS CONTAINING THYMOQUINONE | HUANG, GIGI GEORGIANA | 31d overdue |
| 18545418 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | RICCI, CRAIG D | — |
| 17226651 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18545418 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | RICCI, CRAIG D | 1611 | §102§103Other | Final Rejection | — | Pending | Dec 19, 2023 |
| 17868358 | METHODS OF PREPARING COMPOSITIONS CONTAINING THYMOQUINONE | HUANG, GIGI GEORGIANA | 1613 | §103§112 | Final Rejection | 31d overdue | Pending | Jul 19, 2022 |
| 17226651 | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | RICCI, CRAIG D | 1611 | §102DP | Final Rejection | — | Pending | Apr 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial